Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19012840 | POLYSACCHARIDE COMPOUND WITH A DEFINED MOLECULAR STRUCTURE THAT CAN ELIMINATE THE TOXIC SIDE EFFECTS OF CHEMOTHERAPY DRUGS | January 2025 | June 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 18948016 | PEONY STAMEN-DODDER COMPOSITE, AND ITS PREPARATION METHOD AND APPLICATION | November 2024 | January 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18926515 | GAME ATTRACTANT AND VARMINT REPELLENT COMPOSITIONS AND METHODS | October 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18911447 | MEDICINAL MUSHROOM-BASED TOPICAL COMPOSITION | October 2024 | January 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 18844892 | METHOD FOR IMPROVING HEALTH CONDITION OF MAMMAL OR FARM ANIMAL | September 2024 | February 2025 | Allow | 5 | 0 | 0 | No | No |
| 18794793 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME | August 2024 | January 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 18764014 | FORMULATIONS AND METHODS FOR SKIN CARE | July 2024 | December 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18757390 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | June 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18750691 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | June 2024 | March 2025 | Allow | 9 | 2 | 1 | No | No |
| 18736592 | TRADITIONAL CHINESE MEDICINE COMPOUND FOR PREVENTING AND TREATING AFRICAN SWINE FEVER, AND ITS EFFICIENCY ENHANCEMENT PROCESS AND APPLICATION | June 2024 | October 2024 | Allow | 5 | 0 | 1 | No | No |
| 18736009 | PEST CONTROL USING NATURAL PEST CONTROL AGENT BLENDS | June 2024 | January 2025 | Allow | 8 | 2 | 1 | Yes | No |
| 18734602 | PHARMACEUTICAL COMPOSITION AND COSMETIC COMPOSITION | June 2024 | April 2025 | Allow | 10 | 0 | 1 | Yes | No |
| 18669211 | Composition for Relieving Sleep Disorder and its Application Method Thereof | May 2024 | December 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18667139 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY | May 2024 | January 2025 | Allow | 8 | 0 | 0 | Yes | No |
| 18661900 | COMPOSITION FOR TREATING BONE LOSS | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18659701 | COMPOSITIONS OF HERBAL FORMULATIONS AND USES THEREOF | May 2024 | May 2025 | Allow | 13 | 0 | 1 | Yes | No |
| 18655974 | STABILIZED COMPOSITIONS COMPRISING CANNABIDIOL | May 2024 | January 2025 | Allow | 9 | 0 | 1 | Yes | No |
| 18654377 | BARRIER GUARD TECHNOLOGY | May 2024 | December 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18639285 | METHODS OF TREATING ENDOMETRIOSIS AND OTHER NONCANCER GYNECOLOGICAL DISORDERS WITH HEMP EXTRACT | April 2024 | May 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18635597 | METHODS OF TREATING OVARIAN CANCER WITH HEMP EXTRACT | April 2024 | June 2025 | Allow | 14 | 1 | 0 | No | No |
| 18621062 | TRADITIONAL CHINESE MEDICINE COMPOUND FOR IMPROVING TESTICULAR DYSFUNCTION, PREPARATION METHOD AND APPLICATION THEREOF | March 2024 | October 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18436468 | FOODS TO PROMOTE BETTER HEALTH AND/OR TO MAINTAIN HOMEOSTAIS AND METHOD OF PRODUCTION THEREOF | February 2024 | December 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18432512 | TIME RELEASE SLEEP AID SYSTEM | February 2024 | May 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18429310 | SUSTAINABLE NANOCOMPOSITION FOR TREATMENT OF OSTEOPOROSIS | January 2024 | June 2024 | Allow | 5 | 0 | 1 | No | No |
| 18410512 | PHYTOCHEMICAL/ NUTRACEUTICAL COMPOSITION FOR MULTIMODAL PROPHYLAXIS AGAINST AND TREATMENT OF VIRAL AND BACTERIAL INFECTION AND INFLAMMATION | January 2024 | May 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18407411 | METHOD OF PREVENTING CADMIUM-INDUCED LIVER TOXICITY USING A PLANT PRODUCT DERIVED FROM ACHILLEA MILLEFOLIUM L. | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18391194 | METHOD OF TREATING ILLNESS USING LYOPHILIZED CAMEL URINE | December 2023 | September 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18538812 | BOTANICAL FORMULATIONS | December 2023 | December 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18533558 | AQUEOUS WOUND HEALING FORMULATION | December 2023 | June 2025 | Abandon | 18 | 1 | 1 | Yes | No |
| 18529504 | COMPOSITION FOR TREATING BONE LOSS | December 2023 | April 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18515789 | CRYSTALLINE FORMS OF PSILACETIN | November 2023 | August 2024 | Allow | 9 | 0 | 1 | Yes | No |
| 18512157 | PEST CONTROL USING NATURAL PEST CONTROL AGENT BLENDS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18509499 | COMPOSITION FOR PREVENTING OR TREATING GASTRITIS OR PEPTIC ULCER | November 2023 | March 2025 | Allow | 16 | 1 | 0 | No | No |
| 18559889 | USE OF EXTRACELLULAR VESICLES OF RHIZOMA DRYNARIAE IN PREPARATION OF MEDICINE FOR TREATING ORTHOPEDIC DISEASES | November 2023 | April 2025 | Allow | 17 | 1 | 0 | No | No |
| 18505309 | Topical NSAID Formulation with Improved Skin Absorption | November 2023 | February 2025 | Abandon | 15 | 1 | 1 | No | No |
| 18388167 | METHOD OF TREATMENT OF CANCERS | November 2023 | April 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18387298 | MEDICAL TREATMENT COMPOSITION, METHOD OF PREPARATION AND TREATMENT METHOD | November 2023 | June 2024 | Allow | 8 | 0 | 1 | Yes | No |
| 18493997 | STABILIZED COMPOSITIONS COMPRISING CANNABIDIOL | October 2023 | April 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18381439 | PHOSPHOLIPID COMPOSITIONS FOR DELIVERY OF THERAPEUTIC COMPOUNDS | October 2023 | April 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18381558 | BETA-ADRENERGIC AGONIST AND MUSCARINIC ANTAGONIST COMPOSITIONS AND METHODS OF USING | October 2023 | April 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18487399 | UVARIA GRANDIFLORA EXTRACT AS A BOTANICAL FUNGICIDE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | October 2023 | October 2024 | Abandon | 12 | 1 | 1 | No | No |
| 18379955 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TISSUE INJURY AND DISEASE | October 2023 | March 2025 | Allow | 17 | 1 | 0 | No | No |
| 18476580 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | September 2023 | April 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18367577 | Preparation Method of Ginseng Composition with High Ginsenoside Bioavailability | September 2023 | January 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18464967 | Composition for Relieving Sleep Disorder and its Application Method Thereof | September 2023 | April 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18241567 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | September 2023 | April 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18239560 | OIL-BASED INSECTICIDAL AND INSECT REPELLENT COMPOSITIONS | August 2023 | November 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18236081 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY | August 2023 | May 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18228222 | COMPOSITION FOR A FECAL-DERIVED STERILIZED POSTBIOTIC IN ANTI-AGING AND NEUROTHERAPEUTIC APPLICATIONS | July 2023 | June 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18226387 | PROMOTING GROWTH, YIELD, AND SALINITY TOLERANCE OF ACHILLEA FRAGRANTISSIMA | July 2023 | November 2023 | Allow | 4 | 1 | 1 | No | No |
| 18357668 | USE OF ANTRODIA CINNAMOMEA FOR INCREASING ALCOHOL METABOLISM OR/AND HANGOVER | July 2023 | August 2024 | Allow | 13 | 1 | 0 | No | No |
| 18353992 | HORSERADISH AND CINNAMON MIXED EXTRACT COMPOSITION FOR SUPPRESSION OF AVIAN VIRAL EPIDEMIC DISEASES | July 2023 | December 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18353172 | SAPONIN EXTRACTION | July 2023 | July 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18353169 | SAPONIN EXTRACTION | July 2023 | October 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18222187 | ECM HYDROGEL FOR TREATING ESOPHAGEAL INFLAMMATION | July 2023 | January 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18347535 | BLOOD PLASMA-CONTAINING COMPOSITIONS | July 2023 | June 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18216965 | PROCESSES FOR PRODUCING LOW CHLOROPHYLL, HIGH POLAR LIPID COMPOSITIONS FROM ALGAL OILS AND EXTRACTS | June 2023 | June 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18343765 | FREEZE-DRIED NIPA PALM POWDER AND METHOD OF MANUFACTURING THE SAME | June 2023 | September 2023 | Allow | 3 | 1 | 1 | Yes | No |
| 18205792 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | June 2023 | August 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18204345 | Method for preventing or treating diseases related to vascular endothelial cell activity regulation, comprising a step of administering Java pepper extract | May 2023 | June 2024 | Allow | 12 | 1 | 0 | No | No |
| 18326924 | PLASMA COMPOSITIONS AND METHODS OF USE THEREOF | May 2023 | February 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18199613 | SKIN CARE FORMULATIONS | May 2023 | June 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18199481 | TOPICAL CREAMS | May 2023 | December 2024 | Abandon | 19 | 1 | 1 | No | No |
| 18198054 | COSMETIC COMPOSITION | May 2023 | March 2024 | Allow | 10 | 0 | 0 | Yes | No |
| 18197395 | TOPICAL COSMETIC COMPOSITIONS | May 2023 | July 2024 | Allow | 14 | 0 | 0 | Yes | No |
| 18316759 | BRUISE REMOVAL CREAM | May 2023 | October 2023 | Allow | 5 | 0 | 1 | Yes | No |
| 18143528 | NATURAL MOISTURIZER PRODUCTS | May 2023 | May 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18143151 | COMPOSITION AND METHOD OF TREATING FRAGILE SKIN | May 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18141692 | COSMETIC COMPOSITION | May 2023 | June 2024 | Allow | 13 | 1 | 1 | No | No |
| 18136078 | MAGNOLIA EXTRACT CONTAINING COMPOSITIONS | April 2023 | May 2024 | Allow | 13 | 0 | 1 | Yes | No |
| 18136116 | SKIN CARE FORMULATIONS | April 2023 | May 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18299784 | METHODS OF TREATING OVARIAN CANCER WITH HEMP EXTRACT | April 2023 | March 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18299810 | METHODS OF TREATING ENDOMETRIOSIS AND OTHER NONCANCER GYNECOLOGICAL DISORDERS WITH HEMP EXTRACT | April 2023 | April 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18133410 | Vaporized Medicants and Methods of Use | April 2023 | February 2025 | Allow | 22 | 2 | 0 | No | No |
| 18298929 | SUPPLEMENTATION OF BOVINE COLOSTRUM WITH OMEGA-3 FATTY ACIDS | April 2023 | October 2024 | Allow | 19 | 1 | 0 | No | No |
| 18190938 | METHODS OF EXTRACTING MATERIALS FROM PLANT MATERIAL | March 2023 | April 2024 | Abandon | 12 | 1 | 1 | No | No |
| 18123711 | BOTANICAL FORMULATIONS | March 2023 | November 2023 | Allow | 8 | 0 | 0 | No | No |
| 18120689 | TOPICAL COMPOSITIONS | March 2023 | November 2023 | Allow | 8 | 0 | 0 | Yes | No |
| 18119976 | PROCESS TO ENHANCE THE BIOACTIVITY OF ASHWAGANDHA EXTRACTS | March 2023 | December 2024 | Allow | 21 | 0 | 0 | Yes | No |
| 18044559 | INJECTION COMPOSITION CONTAINING ISOLATED MITOCHONDRIA, AND USE THEREOF | March 2023 | June 2025 | Allow | 27 | 0 | 0 | Yes | No |
| 18118686 | Agmatine Compositions for Treatment of Osteoarthritis | March 2023 | October 2023 | Allow | 7 | 1 | 0 | No | No |
| 18114914 | CANNABIS-BASED PRODUCTS AND METHODS | February 2023 | July 2025 | Allow | 28 | 1 | 0 | Yes | No |
| 18169522 | METHODS FOR EXTRACTING COMPOUND FROM GINSENG, GINSENG EXTRACT COMPRISING THE COMPOUND AND COMPOSITION FOR ENHANCING SKIN BARRIER COMPRISING THE SAME | February 2023 | October 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 18104511 | COSMETIC COMPOSITIONS | February 2023 | August 2023 | Allow | 7 | 0 | 0 | Yes | No |
| 18104030 | THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19 | January 2023 | October 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 18094541 | PHYTOCHEMICAL/ NUTRACEUTICAL COMPOSITION FOR MULTIMODAL PROPHYLAXIS AGAINST AND TREATMENT OF VIRAL AND BACTERIAL INFECTION AND INFLAMMATION | January 2023 | September 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 18093126 | NATURAL CRYSTALLINE COLORANT AND PROCESS FOR PRODUCTION | January 2023 | May 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18084009 | Compositions and Methods for Managing or Improving Bone Disorders, Joint Disorders, Cartilage Disorders, or a Combination Thereof | December 2022 | March 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18079638 | MARINE EXTRACT COMPOSITIONS AND METHODS OF USE | December 2022 | September 2023 | Abandon | 10 | 0 | 1 | No | No |
| 17989529 | OIL-BASED INSECTICIDAL AND INSECT REPELLENT COMPOSITIONS | November 2022 | June 2023 | Allow | 7 | 2 | 0 | Yes | No |
| 18056716 | SYSTEM, METHOD, PROCESS AND NUTRIENT-RICH PRODUCT DERIVED FROM WINE DERIVATIVES | November 2022 | September 2023 | Allow | 9 | 0 | 1 | No | No |
| 18051536 | TOPICAL CREAMS | November 2022 | April 2023 | Allow | 15 | 1 | 1 | Yes | No |
| 17975231 | PROCESSES FOR EXTRACTION OF OMEGA-3 CONTAINING BIOMASS OILS FROM DRIED BIOMASS | October 2022 | November 2024 | Abandon | 25 | 1 | 0 | No | No |
| 18050023 | METHODS OF TREATING ENDOMETRIOSIS AND OTHER NON-CANCER GYNECOLOGICAL DISORDERS WITH HEMP EXTRACT | October 2022 | April 2023 | Allow | 5 | 1 | 1 | Yes | No |
| 18049961 | METHODS OF TREATING OVARIAN CANCER WITH HEMP EXTRACT | October 2022 | April 2023 | Allow | 5 | 1 | 1 | Yes | No |
| 17774522 | COSMETIC COMPOSITION FOR PREVENTING SKIN AGING AND REDUCING SKIN WRINKLES, COMPRISING VIBURNUM STELLATO-TOMENTOSUM EXTRACT | October 2022 | April 2025 | Allow | 35 | 1 | 0 | No | No |
| 17968788 | CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONIST | October 2022 | May 2023 | Allow | 7 | 1 | 1 | Yes | No |
| 18046536 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING WOUND, COMPRISING INDIRUBIN DERIVATIVE AS ACTIVE INGREDIENT | October 2022 | May 2023 | Allow | 7 | 0 | 0 | No | No |
| 17963350 | FEED ADDITIVE COMPOSITIONS AND METHODS OF USE | October 2022 | March 2025 | Abandon | 29 | 4 | 1 | No | No |
| 17961218 | NUTRITIONAL COMPOSITION | October 2022 | August 2023 | Allow | 10 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MI, QIUWEN.
With a 30.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MI, QIUWEN works in Art Unit 1655 and has examined 1,913 patent applications in our dataset. With an allowance rate of 67.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 24 months.
Examiner MI, QIUWEN's allowance rate of 67.8% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MI, QIUWEN receive 1.62 office actions before reaching final disposition. This places the examiner in the 43% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MI, QIUWEN is 24 months. This places the examiner in the 70% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +51.8% benefit to allowance rate for applications examined by MI, QIUWEN. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.5% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 30.0% of cases where such amendments are filed. This entry rate is in the 35% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 52.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 44% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 82.4% of appeals filed. This is in the 72% percentile among all examiners. Of these withdrawals, 55.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 46.9% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 4.9% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.